TapImmune Inc. (NASDAQ:MRKR) saw strong trading volume on Tuesday . 1,402,714 shares changed hands during mid-day trading, an increase of 329% from the previous session’s volume of 327,221 shares.The stock last traded at $6.09 and had previously closed at $5.66.
Several analysts have issued reports on the stock. Roth Capital assumed coverage on shares of TapImmune in a research note on Thursday, May 30th. They issued a “buy” rating and a $10.00 target price on the stock. WBB Securities upgraded shares of TapImmune from a “buy” rating to a “strong-buy” rating and set a $7.29 target price on the stock in a research note on Friday, March 29th. Janney Montgomery Scott assumed coverage on shares of TapImmune in a research note on Friday, March 1st. They issued a “buy” rating and a $6.22 target price on the stock. Zacks Investment Research upgraded shares of TapImmune from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research note on Thursday, May 30th. Finally, ValuEngine lowered shares of TapImmune from a “buy” rating to a “hold” rating in a report on Friday, June 7th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.25.
The firm has a market capitalization of $291.07 million, a P/E ratio of -3.83 and a beta of 0.04. The company has a current ratio of 19.73, a quick ratio of 19.73 and a debt-to-equity ratio of 0.01.
An institutional investor recently raised its position in TapImmune stock. Riggs Asset Managment Co. Inc. raised its position in shares of TapImmune Inc. (NASDAQ:MRKR) by 68.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,919 shares of the company’s stock after buying an additional 18,650 shares during the period. Riggs Asset Managment Co. Inc. owned about 0.10% of TapImmune worth $303,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 33.64% of the company’s stock.
TapImmune Company Profile (NASDAQ:MRKR)
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Recommended Story: Rule of 72
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.